Please login to the form below

Not currently logged in

Excellence in Healthcare Professional Education and Support Programmes

Sponsored by

Back to Results


4 Sites Multi-Site National IBD Meeting

by AbbVie with support from Sciterion

Summary of work

Steroids are commonly prescribed to induce remission during flares in ulcerative colitis. Research shows steroid use is associated with serious adverse events. A UK audit showed excessive steroid use in 43% of patients with active UC. A new approach – the ‘treat-to-target’ (T2T) clinical management strategy --  was developed in 2015 supporting the reduction of excessive steroid use along with appropriate treatment escalation to optimise outcomes. This prompted a UK Steering Committee of Gastroenterology KOLs to develop an agenda for a national meeting to provide education around excessive steroid use and potential management strategies. Pre-meeting only 51% of delegates would consider previous steroid use when making treatment and management decisions and just 33.1% of delegates monitoring symptoms and inflammation markers using T2T. Through state-of-the-art technology, the meeting was live broadcast between four main sites with four additional satellite hubs. This secured local speakers to tailor each meeting to local needs whilst maintaining a National KOL-led faculty. The meeting exceeded objectives with over 250 registered delegates; a post-meeting increase of 21% of delegates who would consider previous steroid use, 96% agreed or strongly agreed that the meeting improved their understanding on T2T in clinical practice, and ten centres developed new service pathways including steroid guidance.

Judges' comments

The judges loved the huge amount of engagement achieved by the 4 Sites Multi-Site National IBD Meeting. The satellite concept ensured successful and increasing reach with well measured steps. It was strong, with good honest learnings and nailed the issues faced by these physicians.

Highly commended


IBD Registry Roadshow 2017 - by British Society of Gastroenterology (BSG) with support from Dovetail

OptiMiSe: Delivering Patient-Centric Management in MS through Clinical Behaviour Change - by Sanofi Genzyme with support from Lucid Group

Adults in ADHD Masterclass (AIM) Programme - by Shire with support from CMC

Key dates

Entry deadline 27 August 2020
Extended entry deadline 3 September 2020*
*additional fee applies
Judging Day 1 October 2020
Company of the Year Interviews 22 October 2020
PMEA Event 25 November 2020